EP0804201A1 - Method of treating opportunistic infections with azaspiranes - Google Patents

Method of treating opportunistic infections with azaspiranes

Info

Publication number
EP0804201A1
EP0804201A1 EP95928072A EP95928072A EP0804201A1 EP 0804201 A1 EP0804201 A1 EP 0804201A1 EP 95928072 A EP95928072 A EP 95928072A EP 95928072 A EP95928072 A EP 95928072A EP 0804201 A1 EP0804201 A1 EP 0804201A1
Authority
EP
European Patent Office
Prior art keywords
compound
opportunistic infections
formula
pharmaceutically acceptable
carbon atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95928072A
Other languages
German (de)
French (fr)
Other versions
EP0804201A4 (en
Inventor
Alison Mary Badger
Peter John Bugelski
Danuta J. Herzyk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP0804201A1 publication Critical patent/EP0804201A1/en
Publication of EP0804201A4 publication Critical patent/EP0804201A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Definitions

  • This invention relates to a method of treating opportunistic infections in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a substituted azaspirane.
  • Opportunistic infections are an increasing problem in medicine. Opportunistic infections can be caused by a wide variety of bacteria, viruses, fungi and protozoa, as described in Microbiology 16th edition. Appleton Crofts. NY, 1976, p 405. Of particular interest are e.g. Candida sp.. Pseudomonas sp.. Listeria sp.. Pneumocvstis carinii. Pneumococci. Neisseria sp.. Salmonella sp.. Mvcobacteria sp.. Cryptococcus sp.. Aspergillis sp.. Cryptosporidium sp.. Herpes simplex.
  • Herpes zoster Cytomegalovirus and Toxoplasma sp. These organisms, which are often part of the normal flora, are rarely a cause for concern in normal hosts but, under certain circumstances, can cause serious disease. These circumstances include but are not limited to: prolonged high dose antibiotic therapy, cancer chemotherapy, transplantation and acquired immunodeficiency syndrome (AIDS) .
  • a Biologic Response Modifier i.e., compounds with immunostimulatory activity, e.g. muramylpeptides
  • immunostimulation may be contraindicated.
  • a Biologic Response Modifier would be expected to exacerbate graft rejection of graft versus host disease.
  • simple immunostimulation may accelerate disease progression.
  • Immunomodulatory agents are, in general, not known for their ability to treat opportunistic infections. Further, there is presently no acceptable means for predicting whether a particular class of immunomodulatory agents will have utility in treating opportunistic infections.
  • Badger I discloses compounds of Formula I as a class of novel compounds which induce an immunomodulatory effect which is characterized by the stimulation of suppressor cell activity.
  • This invention relates to a method of treating opportunistic infections in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a compound of the formula
  • R-- and R2 are the same or different and are selected from hydrogen or straight or branched chain alkyl, provided that the total number of carbon atoms contained by Rl and R-2 when taken together is 5-10; or R- ⁇ and R-2 together form a cyclic alkyl group having 3-7 carbon atoms;
  • R3 and R are the same or different and are selected from hydrogen or straight chain alkyl having 1-3 carbon atoms; or R- and R ⁇ are joined together with the nitrogen atom to form a heterocyclic group having 5-8 atoms; or a pharmaceutically acceptable salt or hydrate or solvate thereof.
  • a preferred compound used in the novel method is the dihydrochloride salt of a compound of Formula (I) where Rl and R-2 are propyl, R ⁇ and R 4 are methyl, m is 1 and n is 3 which is N,N-dimethyl-8,8-dipropyl-2-azaspiro[4.5]decane-2- propanamine dihydrochloride.
  • a particularly preferred compound used in the novel method is the dihydrochloride salt of a compound of Formula (I) where R 1 and R2 are propyl, R3 and R 4 are ethyl, m is 1 and n is 3 which is N,N-diethyl-8,8-dipropyl-2- azaspiro[4.5]decane-2-propanamine dihydrochloride.
  • a particularly preferred compound used in the novel method is the dihydrochloride salt of a compound of Formula (I) where R and R-2 are propyl, R3 and R 4 are joined together with the nitrogen to form a piperidine ring, m is 1 and n is 3 which is 8,8-dipropyl-2-azaspiro[4.5]decane-2-piperidinopropyl dihydrochloride.
  • compound A refers to the dihydrochloride salt of a compound of Formula (I) where Rl and R2 are propyl, R3 and R4 are methyl, m is 1 and n is 3 which is N,N-dimethyl-8,8-dipropyl-2-azaspiro[4.5]decane-2- propanamine dihydrochloride.
  • Compound A was tested for its in vivo ability to treat opportunistic infections in Experiment 1.
  • Compound A was dissolved in saline- and administered to CBA/J mice, at 0, 1.5, or 15 mg/kg, by daily intraperitoneal injection for 14 days.
  • Control mice received saline.
  • all mice received an intravenous injection of 1x10 ⁇ Candida Albicans (Strain B311). Survival was monitored daily until all mice died or were sacrificed for humane reasons. There was a significant increase in the mean survival time in the mice that received 15 mg/kg.
  • mice that received intraperitoneal 5 doses of dexamethasone (an immunosuppressive steriod) at 50 mg/kg showed a significant decrease in mean survival time.
  • Compound A was tested in an £i vivo experiment (Experiment 2) for its ability to treat opportunistic infections.
  • Lewis rats received oral doses of 20 mg/kg of Compound A dissolved in 0.5% Tragacanth (5 doses/wk) for 16 days. On day 23 the rats were sacrificed and alveolar macrophages were collected by brochoalveolar lavage. The cells were dispensed into 24 well dishes and their ability to kill Candida albicans evaluated.
  • This invention relates to a method of treating opportunistic infections in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt or hydrate or solvate thereof.
  • a compound of Formula (I) or a pharmaceutically acceptable salt or hydrate or solvate thereof can be administered to such mammal including a human, in a conventional dosage form prepared by combining a compound of Formula (I) or a pharmaceutically acceptable salt or hydrate or solvate thereof, with a conventional pharmaceutically acceptable carrier or diluent according to known techniques, such as those described in Badger (I), U.S. Patent No.4,963,557.
  • a compound of Formula (I) or a pharmaceutically acceptable salt or hydrate or solvate thereof is administered to a mammal, including a human in an amount sufficient to treat opportunistic infections.
  • the route of administration of the Formula (I) ("active ingredient") compound is not critical but is usually oral or parenteral, preferably oral.
  • parenteral as used herein includes intravenous, intramuscular, subcutaneous, intranasal, intrarectal, transdermal, intravaginal or intraperitoneal administration.
  • the subcutaneous and intramuscular forms of parenteral administration are generally preferred.
  • the daily parenteral dosage regimen will preferably be from about 0.01 mg/kg to about 10 mg/kg of total body weight, most preferably from about 0.1 mg/kg to about 1 mg/kg.
  • each parenteral dosage unit will contain the active ingredient in an amount of from about 0.1 mg to about 100 mg.
  • the compounds of Formula (I) which are active when given orally can be formulated as liquids, for example syrups, suspensions or emulsions, tablets, capsules and lozenges.
  • a liquid formulation will generally consist of a suspension or solution of the compound or pharmaceutically acceptable salt in a suitable liquid carriers) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suspending agent, preservative, flavoring or coloring agent.
  • a suitable liquid carriers for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suspending agent, preservative, flavoring or coloring agent.
  • a composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid formulations. Examples of such carriers include magnesium stearate, starch, lactose, sucrose and cellulose.
  • a composition in the form of a capsule can be prepared using routine encapsulation procedures.
  • pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carriers), for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.
  • suitable pharmaceutical carriers for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.
  • the daily oral dosage regimen will preferably be from about 0.01 mg/kg to about 10 mg/kg of total body weight.
  • each oral dosage unit will contain the active ingredient in an amount of from about 0.1 mg to about 100 mg.
  • an active ingredient While it is possible for an active ingredient to be administered alone, it is preferable to present it as a pharmaceutical formulation.
  • the optimal quantity and spacing of individual dosages of a compound of formula (I) or a pharmaceutically acceptable salt or hydrate or solvate thereof will be determined by the nature and extent of the condition being treated, the form, route and site of administration, and the particular patient being treated, and that such optimums can be determined by conventional techniques. It will also be appreciated by one of skill in the art that the optimal course of treatment, i.e., the number of doses of a compound of Formula (I) or a pharmaceutically acceptable salt or hydrate or solvate thereof given per day and duration of therapy, can be ascertained by those skilled in the art using conventional course of treatment determination tests.
  • the method of this invention of treating opportunistic infections in a mammal, including a human comprises administering to a subject in need of such treatment an effective amount of a pharmaceutically active compound of the present invention.
  • the invention also provides for the use of a compound of Formula (I) in the manufacture of a medicament for use in the treatment of opportunistic infections in a mammal, including a human.
  • the invention also provides for a pharmaceutical composition for use in the treatment of opportunistic infections in a mammal, including a human.
  • the invention also provides for a process for preparing a pharmaceutical composition containing a pharmaceutically acceptable carrier or diluent and a compound of Formula I which comprises bringing the compound of Formula I into association with the pharmaceutically acceptable carrier of diluent.
  • FIGURE 1 The effect of N,N-dimethyl-8,8-dipropyl-2-azaspiro[4.5]decane-2- propanamine dihydrochloride (Compound A ) on treating opportunistic infections in vivo from Experiment 1.
  • FIGURE 1 The effect of N,N-dimethyl-8,8-dipropyl-2-azaspiro[4.5]decane-2- propanamine dihydrochloride (Compound A ) on treating opportunistic infections in vivo from Experiment 1.
  • FIGURE 1 The effect of N,N-dimethyl-8,8-dipropyl-2-azaspiro[4.5]decane-2- propanamine dihydrochloride (Compound A ) on treating opportunistic infections in vivo from Experiment 1.
  • FIGURE 1 The effect of N,N-dimethyl-8,8-dipropyl-2-azaspiro[4.5]decane-2- propanamine dihydrochloride
  • the compounds of the present invention can be co-administered with further active ingredients, such as compounds known to treat opportunistic infections
  • EXAMPLE 1 - CAPSULE COMPOSITION An oral dosage form for administering Formula (I) compounds is produced by filing a standard two piece hard gelatin capsule with the ingredients in the proportions shown in Table II, below.
  • An injectable form for administering Formula (I) compounds is produced by stirring 1.5% by weight of N,N-diethyl-8,8-dipropyl-2-azaspiro[4,5]decane-2- propanamine dihydrochloride in 10% by volume propylene glycol in water.
  • sucrose, calcium sulfate dihydrate and Formula (I) compound shown in Table III below are mixed and granulated in the proportions shown with a 10% gelatin solution.
  • the wet granules are screened, dried, mixed with the starch, talc and stearic acid, screened and compressed into a tablet.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Invented is a method of treating opportunistic infections in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a substituted azaspirane.

Description

METHOD OF TREATING OPPORTUNISTIC INFECTIONS WITH AZASPIRANES
This invention relates to a method of treating opportunistic infections in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a substituted azaspirane.
Background of the Invention Opportunistic infections are an increasing problem in medicine. Opportunistic infections can be caused by a wide variety of bacteria, viruses, fungi and protozoa, as described in Microbiology 16th edition. Appleton Crofts. NY, 1976, p 405. Of particular interest are e.g. Candida sp.. Pseudomonas sp.. Listeria sp.. Pneumocvstis carinii. Pneumococci. Neisseria sp.. Salmonella sp.. Mvcobacteria sp.. Cryptococcus sp.. Aspergillis sp.. Cryptosporidium sp.. Herpes simplex. Herpes zoster. Cytomegalovirus and Toxoplasma sp. These organisms, which are often part of the normal flora, are rarely a cause for concern in normal hosts but, under certain circumstances, can cause serious disease. These circumstances include but are not limited to: prolonged high dose antibiotic therapy, cancer chemotherapy, transplantation and acquired immunodeficiency syndrome (AIDS) . In the first two examples cited, a Biologic Response Modifier, (i.e., compounds with immunostimulatory activity, e.g. muramylpeptides ) would be the adjunct treatment of choice for an opportunistic infection ( Walsh TH et al. Curr Opin Oncol 4:647- 655, 1992). In the latter two examples, however, immunostimulation may be contraindicated. In the case of transplantation, a Biologic Response Modifier would be expected to exacerbate graft rejection of graft versus host disease. In ALDS, simple immunostimulation may accelerate disease progression.
Immunomodulatory agents are, in general, not known for their ability to treat opportunistic infections. Further, there is presently no acceptable means for predicting whether a particular class of immunomodulatory agents will have utility in treating opportunistic infections.
Badger, et al., U.S. Patent No. 4,963,557 (Badger I) discloses compounds of the formula I:
(I) wherein: n is 3-7; m is 1 or 2; R-* and R-2 are the same or different and are selected from hydrogen or straight or branched chain alkyl, provided that the total number of carbon atoms contained by R-* and R2 when taken together is 5-10; or R! and R2 together form a cyclic alkyl group having 3-7 carbon atoms; R-^ and R^ are the same or different and are selected from hydrogen or straight chain alkyl having 1-3 carbon atoms; or R^ and R^ are joined together with the nitrogen atom to form a heterocyclic group having 5-8 atoms; or a pharmaceutically acceptable salt or hydrate or solvate thereof.
Badger I discloses compounds of Formula I as a class of novel compounds which induce an immunomodulatory effect which is characterized by the stimulation of suppressor cell activity.
Badger I does not disclose the compounds of Formula I as agents for treating opportunistic infections.
Summary of the Invention
This invention relates to a method of treating opportunistic infections in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a compound of the formula
(I) wherein: n is 3-7; m is 1 or 2;
R-- and R2 are the same or different and are selected from hydrogen or straight or branched chain alkyl, provided that the total number of carbon atoms contained by Rl and R-2 when taken together is 5-10; or R-^ and R-2 together form a cyclic alkyl group having 3-7 carbon atoms;
R3 and R are the same or different and are selected from hydrogen or straight chain alkyl having 1-3 carbon atoms; or R- and R^ are joined together with the nitrogen atom to form a heterocyclic group having 5-8 atoms; or a pharmaceutically acceptable salt or hydrate or solvate thereof.
Detailed Description of the Invention The preparation of all compounds of Formula (I) and pharmaceutically acceptable salts, hydrates and solvates and formulations thereof is disclosed in U.S. Patent No. 4,963,557, the entire disclosure of which is hereby incorporated by reference. A preferred compound used in the novel method is the dihydrochloride salt of a compound of Formula (I) where Rl and R-2 are propyl, R^ and R4 are methyl, m is 1 and n is 3 which is N,N-dimethyl-8,8-dipropyl-2-azaspiro[4.5]decane-2- propanamine dihydrochloride.
A particularly preferred compound used in the novel method is the dihydrochloride salt of a compound of Formula (I) where R 1 and R2 are propyl, R3 and R4 are ethyl, m is 1 and n is 3 which is N,N-diethyl-8,8-dipropyl-2- azaspiro[4.5]decane-2-propanamine dihydrochloride.
A particularly preferred compound used in the novel method is the dihydrochloride salt of a compound of Formula (I) where R and R-2 are propyl, R3 and R4 are joined together with the nitrogen to form a piperidine ring, m is 1 and n is 3 which is 8,8-dipropyl-2-azaspiro[4.5]decane-2-piperidinopropyl dihydrochloride.
As used herein, the term "compound A" refers to the dihydrochloride salt of a compound of Formula (I) where Rl and R2 are propyl, R3 and R4 are methyl, m is 1 and n is 3 which is N,N-dimethyl-8,8-dipropyl-2-azaspiro[4.5]decane-2- propanamine dihydrochloride.
It has now been discovered that compounds of Formula (I) and pharmaceutically acceptable salts or hydrates or solvates thereof are useful for treating opportunistic infections in a mammal, including a human, in need thereof. By the term "treating" is meant prophylactic or therapeutic therapy.
Compound A was tested for its in vivo ability to treat opportunistic infections in Experiment 1. To perform Experiment 1 Compound A was dissolved in saline- and administered to CBA/J mice, at 0, 1.5, or 15 mg/kg, by daily intraperitoneal injection for 14 days. Control mice received saline. On day 8, all mice received an intravenous injection of 1x10^ Candida Albicans (Strain B311). Survival was monitored daily until all mice died or were sacrificed for humane reasons. There was a significant increase in the mean survival time in the mice that received 15 mg/kg. In contrast, mice that received intraperitoneal 5 doses of dexamethasone (an immunosuppressive steriod) at 50 mg/kg showed a significant decrease in mean survival time. Compound A was tested in an £i vivo experiment (Experiment 2) for its ability to treat opportunistic infections. In Experiment 2 Lewis rats received oral doses of 20 mg/kg of Compound A dissolved in 0.5% Tragacanth (5 doses/wk) for 16 days. On day 23 the rats were sacrificed and alveolar macrophages were collected by brochoalveolar lavage. The cells were dispensed into 24 well dishes and their ability to kill Candida albicans evaluated. There was a significant increase in the ability of cells from rats treated with Compound A to kill two strains (B311 and B792) of Candida. Compound A was tested in an in vitro experiment (Experiment 3) for its ability to treat opportunistic infections. In Experiment 3 alveolar macrophges were collected by lavage from untreated rats and were incubated with Compound A i vitro for 3 days. At that time, the compound was washed off and the cells ability to kill Candida albicans (Strain B792) was evaluated. There was a statistically significant concentration dependent increase in kill percentage at ≥ uM Compound A. This effect is not due to a direct effect of Compound A on the growth of Candida albicans as concentrations up to 12 uM had no effect on the yeast.
This invention relates to a method of treating opportunistic infections in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt or hydrate or solvate thereof. A compound of Formula (I) or a pharmaceutically acceptable salt or hydrate or solvate thereof can be administered to such mammal including a human, in a conventional dosage form prepared by combining a compound of Formula (I) or a pharmaceutically acceptable salt or hydrate or solvate thereof, with a conventional pharmaceutically acceptable carrier or diluent according to known techniques, such as those described in Badger (I), U.S. Patent No.4,963,557.
It will be recognized by one of skill in the art that the form and character of the pharmaceutically acceptable carrier or diluent is dictated by the amount of active ingredient with which it is to be combined, the route of administration and other well-known variables. A compound of Formula (I) or a pharmaceutically acceptable salt or hydrate or solvate thereof is administered to a mammal, including a human in an amount sufficient to treat opportunistic infections. The route of administration of the Formula (I) ("active ingredient") compound is not critical but is usually oral or parenteral, preferably oral. The term parenteral as used herein includes intravenous, intramuscular, subcutaneous, intranasal, intrarectal, transdermal, intravaginal or intraperitoneal administration. The subcutaneous and intramuscular forms of parenteral administration are generally preferred. The daily parenteral dosage regimen will preferably be from about 0.01 mg/kg to about 10 mg/kg of total body weight, most preferably from about 0.1 mg/kg to about 1 mg/kg. Preferably, each parenteral dosage unit will contain the active ingredient in an amount of from about 0.1 mg to about 100 mg.
The compounds of Formula (I) which are active when given orally can be formulated as liquids, for example syrups, suspensions or emulsions, tablets, capsules and lozenges.
A liquid formulation will generally consist of a suspension or solution of the compound or pharmaceutically acceptable salt in a suitable liquid carriers) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suspending agent, preservative, flavoring or coloring agent. A composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid formulations. Examples of such carriers include magnesium stearate, starch, lactose, sucrose and cellulose. A composition in the form of a capsule can be prepared using routine encapsulation procedures. For example, pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carriers), for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule. The daily oral dosage regimen will preferably be from about 0.01 mg/kg to about 10 mg/kg of total body weight. Preferably each oral dosage unit will contain the active ingredient in an amount of from about 0.1 mg to about 100 mg.
While it is possible for an active ingredient to be administered alone, it is preferable to present it as a pharmaceutical formulation.
It will be recognized by one of skill in the art that the optimal quantity and spacing of individual dosages of a compound of formula (I) or a pharmaceutically acceptable salt or hydrate or solvate thereof will be determined by the nature and extent of the condition being treated, the form, route and site of administration, and the particular patient being treated, and that such optimums can be determined by conventional techniques. It will also be appreciated by one of skill in the art that the optimal course of treatment, i.e., the number of doses of a compound of Formula (I) or a pharmaceutically acceptable salt or hydrate or solvate thereof given per day and duration of therapy, can be ascertained by those skilled in the art using conventional course of treatment determination tests.
The method of this invention of treating opportunistic infections in a mammal, including a human, comprises administering to a subject in need of such treatment an effective amount of a pharmaceutically active compound of the present invention.
The invention also provides for the use of a compound of Formula (I) in the manufacture of a medicament for use in the treatment of opportunistic infections in a mammal, including a human.
The invention also provides for a pharmaceutical composition for use in the treatment of opportunistic infections in a mammal, including a human.
The invention also provides for a process for preparing a pharmaceutical composition containing a pharmaceutically acceptable carrier or diluent and a compound of Formula I which comprises bringing the compound of Formula I into association with the pharmaceutically acceptable carrier of diluent.
No unacceptable toxicological effects are expected when compounds of the invention are administered in accordance with the present invention.
Following are the results of testing the compounds of this invention.
Figure I The effect of N,N-dimethyl-8,8-dipropyl-2-azaspiro[4.5]decane-2- propanamine dihydrochloride (Compound A ) on treating opportunistic infections in vivo from Experiment 1. FIGURE 1
EFFECT OF DRUG TREATMENT ON SURVIVAL AFTER CANDIDA ALBICANS INJECTION
IN CBA/J MICE
A [1 A [1.
7 8 10 11 12 13 14 15
DAYS
Table I The effect of N,N-dimethyl-8,8-dipropyl-2-azaspiro[4.5]decane-2- propanamine dihydrochloride (Compound A) on treating opportunistic infections ex vivo from Experiment 2.
Table 1
Effect of Candidacidal Activity of Rat Bronchoalveolar Cells
* Significantly greater than control, P<0.001
Figure 2 The effect of N,N-dimethyl-8,8-dipropyl-2-azaspiro[4.5]decane-2- propanamine dihydrochloride (Compound A) on treating opportunistic infections in vitro from Experiment 3.
Figure 2
Effect of Compound (A) on Candidacidal Activity of Rat Alveolar Macrophages
Compound (A) (uM)
The data in the above figures and table, from in vivo, ex vivo and in vitro experiments, demonstrates the unexpected therapeutic effect of compounds of Formula I on treating opportunistic infections.
In addition, the compounds of the present invention can be co-administered with further active ingredients, such as compounds known to treat opportunistic infections
Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following examples are, therefore, to be construed as merely illustrative and not a limitation of the scope of the present invention in any way.
EXAMPLE 1 - CAPSULE COMPOSITION An oral dosage form for administering Formula (I) compounds is produced by filing a standard two piece hard gelatin capsule with the ingredients in the proportions shown in Table II, below.
An injectable form for administering Formula (I) compounds is produced by stirring 1.5% by weight of N,N-diethyl-8,8-dipropyl-2-azaspiro[4,5]decane-2- propanamine dihydrochloride in 10% by volume propylene glycol in water.
Example 3 - Tablet Composition
The sucrose, calcium sulfate dihydrate and Formula (I) compound shown in Table III below, are mixed and granulated in the proportions shown with a 10% gelatin solution. The wet granules are screened, dried, mixed with the starch, talc and stearic acid, screened and compressed into a tablet.
While the above descriptions and examples fully describe the invention and the preferred embodiments thereof, it is understood that the invention is not limited to the particular disclosed embodiments coming within the scope of the following claims.

Claims

What is claimed is:
1. A method for treating opportunistic infections in a mammal including a human, in need thereof, which comprises administering to such human an effective amount of a compound of the formula
wherein:
n is 3-7;
m is 1 or 2;
R1 and R2 are the same or different and are selected from hydrogen or straight or branched chain alkyl, provided that the total number of carbon atoms contained by R1 and R2 when taken together is 5-10; or R1 and R2 together form a cyclic alkyl group having 3-7 carbon atoms; R3 and R4 are the same or different and are selected from hydrogen or straight chain alkyl having 1-3 carbon atoms; or R3 and R4 are joined together with the nitrogen to form a heterocyclic group having 5-8 atoms;
or a pharmaceutically acceptable salt or hydrate or solvate thereof.
2. The method of claim 1 wherein the compound is N,N-diethyl-8,8- dipropyl-2-azaspiro[4.5]decane-2-propanamine;
or a pharmaceutically acceptable salt, hydrate or solvate thereof.
3. The method of claim 1 wherein the compound is administered orally.
4. The method of claim 3 wherein from about 0.01 mg/kg to about 10 mg/kg of compound is administered per day.
5. The method of claim 1 wherein the compound is administered parenterally.
6. The method of claim 5 wherein from about 0.01 mg/kg to about mg/kg of compound is administered per day.
EP95928072A 1994-07-23 1995-07-14 Method of treating opportunistic infections with azaspiranes Withdrawn EP0804201A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9414902A GB9414902D0 (en) 1994-07-23 1994-07-23 Methods
GB9414902 1994-07-23
PCT/US1995/008915 WO1996003126A1 (en) 1994-07-23 1995-07-14 Method of treating opportunistic infections with azaspiranes

Publications (2)

Publication Number Publication Date
EP0804201A1 true EP0804201A1 (en) 1997-11-05
EP0804201A4 EP0804201A4 (en) 2000-04-26

Family

ID=10758802

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95928072A Withdrawn EP0804201A4 (en) 1994-07-23 1995-07-14 Method of treating opportunistic infections with azaspiranes

Country Status (15)

Country Link
EP (1) EP0804201A4 (en)
JP (1) JPH10503202A (en)
KR (1) KR970704446A (en)
CN (1) CN1157564A (en)
AU (1) AU684384B2 (en)
BR (1) BR9508332A (en)
CA (1) CA2195778A1 (en)
CZ (1) CZ286482B6 (en)
GB (1) GB9414902D0 (en)
HU (1) HUT77379A (en)
MX (1) MX9700626A (en)
NO (1) NO310096B1 (en)
NZ (1) NZ290974A (en)
WO (1) WO1996003126A1 (en)
ZA (1) ZA956098B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9601909A (en) * 1995-07-13 1999-10-13 Smithkline Beecham Corp N, n-diethyl-8,8-dipropyl-2-azaspiro (4,5) decane-2-propan amine dimaleate

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992014462A1 (en) * 1991-02-19 1992-09-03 Smithkline Beecham Corporation Cytokine inhibitors
WO1992022294A1 (en) * 1991-06-07 1992-12-23 Smithkline Beecham Corporation Immunomodulatory azaspiranes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963557A (en) * 1987-09-28 1990-10-16 Smithkline Beecham Corporation Immunomodulatory azaspiranes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992014462A1 (en) * 1991-02-19 1992-09-03 Smithkline Beecham Corporation Cytokine inhibitors
WO1992022294A1 (en) * 1991-06-07 1992-12-23 Smithkline Beecham Corporation Immunomodulatory azaspiranes

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BADGER A M ET AL.: "Effects of SK&F 105685, a novel anti-arthritic agent, on immune function in the dog" INT. J. IMMUNOPHARMACOL., vol. 15, no. 2, 1993, pages 113-123, XP002106846 *
BADGER A M ET AL: "BENEFICIAL EFFECTS OF SK&F 105685 IN RAT ADJUVANT ARTHRITIS: PROPHYLACTIC AND THERAPEUTIC EFFECTS ON DISEASE PARAMETER PROGRESSION" INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, vol. 15, no. 3, 1 January 1993 (1993-01-01), pages 343-347, 349 - 35, XP000677832 *
BADGER A M ET AL: "THERAPEUTIC ACTIVITY OF SK&F 105685, A NOVEL AZASPIRANE WITH SUPPRESSOR-CELL INDUCING ACTIVITY" CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, vol. 11, no. SUPPL. 08, 1 March 1993 (1993-03-01), pages S107-S109, XP000677527 *
See also references of WO9603126A1 *

Also Published As

Publication number Publication date
ZA956098B (en) 1996-05-23
CZ20997A3 (en) 1997-10-15
HU9700201D0 (en) 1997-04-28
CN1157564A (en) 1997-08-20
NO970284L (en) 1997-03-19
NO970284D0 (en) 1997-01-22
KR970704446A (en) 1997-09-06
NZ290974A (en) 1999-08-30
AU684384B2 (en) 1997-12-11
CZ286482B6 (en) 2000-04-12
BR9508332A (en) 1997-11-04
GB9414902D0 (en) 1994-09-14
HUT77379A (en) 1998-04-28
AU3190995A (en) 1996-02-22
NO310096B1 (en) 2001-05-21
EP0804201A4 (en) 2000-04-26
WO1996003126A1 (en) 1996-02-08
JPH10503202A (en) 1998-03-24
CA2195778A1 (en) 1996-02-08
MX9700626A (en) 1997-05-31

Similar Documents

Publication Publication Date Title
EP0651642A1 (en) Use of 1,3-dicyclopropymethyl-8-amino-xanthine for the treatment and prevention of type ii diabetes mellitus and obesity
HUT71235A (en) Pharmaceutical compositions against endometriosis containing 2-phenyl-3-aroil-benzotiophene derivatives and process for their preparation
US5786376A (en) Methods of treating opportunistic infections with azaspiranes
AU684384B2 (en) Method of treating opportunistic infections with azaspiranes
AU7370894A (en) Method of inhibiting the production of human immunodeficiency viruses with substituted azaspiranes
US5482959A (en) Method for delaying aids in an HIV infected individual by administration of substituted azaspirane compounds
AU7514094A (en) Methods of treating hiv with azaspiranes
AU7370994A (en) Method of inhibiting the replication of human immunodeficiency viruses with substituted azaspiranes
WO1993014760A2 (en) Methods
AU710542B2 (en) Use of substituted azaspirane in the treatment of asthma
WO1993007869A1 (en) Methods for treatment of hyperlipidemia using azaspiranes
CZ119197A3 (en) Benzothiophene for preparing a medicament
JPH09500647A (en) A method for inhibiting human immunodeficiency virus production by substituted azaspirans.
EP0752856A1 (en) Methods of treating hyperlipidemia
MXPA98009596A (en) Use of azaspiran substituted in the treatment of a

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970221

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: SI PAYMENT 970221

A4 Supplementary search report drawn up and despatched

Effective date: 20000315

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20000523

18RA Request filed for re-establishment of rights before grant

Effective date: 20010405